Roche Holding stock trades on report context after 2025 sales and profit growth

Roche Holding stock is supported by 2025 sales of CHF 60.5 billion, core EPS growth of 8%, and a 6% dividend increase.

Roche Holding (CH0012032048) is anchored by 2025 sales of CHF 60.5 billion, core earnings per share of CHF 19.62, and a proposed dividend of CHF 9.70 per share. The figures come from Roche’s 2025 results context, which also showed 7% sales growth at constant exchange rates and 8% growth in core EPS.

Sales rose 7%

Roche reported 2025 group sales of CHF 60.5 billion, up 7% at constant exchange rates, while the pharmaceutical division generated CHF 46.2 billion and diagnostics contributed CHF 14.3 billion. Core operating profit reached CHF 21.5 billion in 2025, giving the group a core operating margin of 35.6%.

The comparison matters for Roche Holding stock because the margin and earnings line show how much of the sales gain turned into profit. Core EPS climbed 8% to CHF 19.62 in 2025, a cleaner signal than revenue alone for investors tracking operating leverage.

Margin reached 35.6%

Roche also said it expects a mid-single-digit sales increase in 2026, with core EPS still targeted to grow broadly in line with sales. That guidance keeps the emphasis on execution in pharmaceuticals and on the diagnostics base that added CHF 14.3 billion in 2025 revenue.

For Roche Holding stock, the 2025 mix is more important than a headline growth rate because the pharmaceutical segment delivered the bulk of group sales. A stronger mix supports the 35.6% core operating margin and leaves room for further earnings conversion if 2026 sales progress as guided.

Diagnostics brought CHF 14.3 billion

Diagnostics remained a meaningful second engine with CHF 14.3 billion in 2025 sales, while pharmaceuticals contributed CHF 46.2 billion. That split matters because Roche Holding stock is still driven primarily by pharma launches, but diagnostics helps stabilize the revenue base.

Core net income was CHF 17.6 billion in 2025, and the board proposed a dividend of CHF 9.70 per share, up 6% from CHF 9.20. The dividend change gives a clear year-over-year comparison and shows how management translated earnings into shareholder returns.

Pharma still leads

In the product mix, Roche continued to lean on its medicines portfolio, which generated most of the 2025 group revenue. The company’s 2026 guidance for mid-single-digit sales growth suggests the next move will depend on whether that base can keep expanding without margin dilution.

That is why Roche Holding stock is being read through sales quality, not just sales volume. Investors are likely to focus on whether the CHF 21.5 billion core operating profit and 35.6% margin can be defended as the 2026 mix evolves.

Stock closing view

Roche Holding stock is quoted on SIX Swiss Exchange as a CHF-denominated large-cap healthcare name. A dated live price was not available in the available material, so the most recent hard market context in this article remains the company’s 2025 operating base and 2026 guidance.

Roche Holding stock facts

• Company: Roche Holding AG
• ISIN: CH0012032048
• Ticker: SIX: ROG
• Trading venue: SIX Swiss Exchange
• Sector / Industry: Healthcare / Pharmaceuticals
• Index membership: Swiss Market Index